checkAd

     411  0 Kommentare Mallinckrodt Announces Study Demonstrating Effectiveness of ECP Immunomodulation, as an adjunct to local standard therapy, in Treatment of Lung Transplant Patients with Bronchiolitis Obliterans Syndrome (BOS)

    -- Retrospective study shows that ECP when added to standard local therapy improves survival probability by approximately 30% in lung transplant patients diagnosed with BOS compared to matched controls --

    -- Adjunct ECP therapy also shown to lower hospital-related expenses for BOS patients --

    STAINES-UPON-THAMES, United Kingdom, April 5, 2019 /PRNewswire/ -- Mallinckrodt plc (NYSE: MNK), a leading specialty pharmaceutical company, announces the presentation of a retrospective study that demonstrates the effectiveness of Extracorporeal Photopheresis (ECP), as an adjunct to local standard therapy, in lung transplant recipients with Bronchiolitis Obliterans Syndrome (BOS)1.

    Mallinckrodt logo

    The study, led by Dr. Christian Joukhadar of J&P Medical Study Ltd., will be delivered in an oral presentation on Friday, 5 April, 2019 at the 39th Annual Meeting and Scientific Sessions of the International Society for Heart and Lung Transplantation (ISHLT) in Orlando, Florida, USA. Mallinckrodt supported the publication of the study.

    Dr. Joukhadar's work addressed the use of ECP at the Medical University of Vienna as an empiric treatment option for lung transplant recipients suffering from BOS. The study sought to evaluate hospital-related costs and the clinical value of ECP when applied as an adjunct to the local standard therapy of BOS compared to standard treatment alone.  UVAR XTS was the ECP technology used in this study.

    The retrospective study reveals that, compared to standard BOS-directed therapies alone, the addition of ECP significantly improves survival probability in double-lung transplant patients diagnosed with BOS. Over the observation period of up to 15.5 years, survival probability was improved by approximately 30% in the ECP-treated patients as compared to matched controls.2

    In addition, it was found the addition of ECP to standard therapy exerts a substantially positive impact on the number of total re-admissions to the hospital, the total days of care, and the total patient days, as compared to treatment with standard therapy alone. The study concludes "ECP has proved highly effective and cost saving in the treatment of lung transplant patients presenting with BOS." 3

    "Mallinckrodt, a pioneer in the development and delivery of ECP immunomodulation, is pleased to see this study's evidence of the clinical efficacy in lung transplant recipients with BOS, and the notable cost savings this therapy can provide for hospitals," said Steven Romano, M.D., Executive Vice President and Chief Scientific Officer of Mallinckrodt. "We are proud to support efforts to evaluate ECP in this critical area of patient care."

    Seite 1 von 4


    PR Newswire (engl.)
    0 Follower
    Autor folgen

    Verfasst von PR Newswire (engl.)
    Mallinckrodt Announces Study Demonstrating Effectiveness of ECP Immunomodulation, as an adjunct to local standard therapy, in Treatment of Lung Transplant Patients with Bronchiolitis Obliterans Syndrome (BOS) - Retrospective study shows that ECP when added to standard local therapy improves survival probability by approximately 30% in lung transplant patients diagnosed with BOS compared to matched controls - - Adjunct ECP therapy also shown to lower …